EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect

ALK rearrangements; Crizotinib; EGFR mutations; Erlotinib; KRAS mutations; Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Copy Number Variations; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Receptor Protein-Tyrosine Kinases; Receptor, Epidermal Growth Factor; Oncology; Pulmonary and Respiratory Medicine; Cancer Research